Top

Published in:

Open Access 23-05-2023 | Gastric Cancer | Review

Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis

Authors: Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi

Published in: Journal of Gastrointestinal Cancer | Issue 4/2023

Abstract

Purpose

Although second-line treatments improve survival compared to best supportive care in patients with advanced gastric cancer with disease progression on first-line therapy, prognosis remains poor. A systematic review and meta-analysis were conducted to quantify the efficacy of second-or-later line systemic therapies in this target population.

Methods

A systematic literature review (January 1, 2000 to July 6, 2021) of Embase, MEDLINE, and CENTRAL with additional searches of 2019–2021 annual ASCO and ESMO conferences was conducted to identify studies in the target population. A random-effects meta-analysis was performed among studies involving chemotherapies and targeted therapies relevant in treatment guidelines and HTA activities. Outcomes of interest were objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) presented as Kaplan–Meier data. Randomized controlled trials reporting any of the outcomes of interest were included. For OS and PFS, individual patient-level data were reconstructed from published Kaplan–Meier curves.

Results

Forty-four trials were eligible for the analysis. Pooled ORR (42 trials; 77 treatment arms; 7256 participants) was 15.0% (95% confidence interval (CI) 12.7–17.5%). Median OS from the pooled analysis (34 trials; 64 treatment arms; 60,350 person-months) was 7.9 months (95% CI 7.4–8.5). Median PFS from the pooled analysis (32 trials; 61 treatment arms; 28,860 person-months) was 3.5 months (95% CI 3.2–3.7).

Conclusion

Our study confirms poor prognosis among patients with advanced gastric cancer, following disease progression on first-line therapy. Despite the approved, recommended, and experimental systemic treatments available, there is still an unmet need for novel interventions for this indication.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England). 2019;393(10184):1948–57. https://doi.org/10.1016/s0140-6736(18)32557-1.CrossRefPubMed

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.CrossRefPubMed

Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol: Official J Am Soc Clin Oncol. 2011;29(13):1715–21. https://doi.org/10.1200/jco.2010.33.0597.CrossRef

Society AC. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20.CrossRefPubMed

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022 Feb 1;20(2):167–92.

Cotes Sanchís A, Gallego J, Hernandez R, Arrazubi V, Custodio A, Cano JM, et al. Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry. PloS One. 2020;15(7):e0235848. https://doi.org/10.1371/journal.pone.0235848.

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86. https://doi.org/10.1016/s1470-2045(13)70549-7.CrossRefPubMed

10.

Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014;105(7):812–7. https://doi.org/10.1111/cas.12419.CrossRefPubMedPubMedCentral

11.

Zhang DS, Jin Y, Luo HY, Wang ZQ, Qiu MZ, Wang FH, et al. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer. 2015;112(2):266–70. https://doi.org/10.1038/bjc.2014.607.CrossRefPubMed

12.

Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol : Official J Am Soc Clin Oncol. 2010;28(11):1904–10. https://doi.org/10.1200/jco.2009.26.2923.

13.

Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer (Oxford, England : 1990). 2012;48(4):510–7. https://doi.org/10.1016/j.ejca.2011.12.005.

14.

Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44. https://doi.org/10.1200/JCO.2012.48.5805.CrossRefPubMed

15.

Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50(8):1437–45. https://doi.org/10.1016/j.ejca.2014.01.020.CrossRefPubMed

16.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. https://doi.org/10.1016/S0140-6736%2813%2961719-5.CrossRefPubMed

17.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045%2814%2970420-6.CrossRefPubMed

18.

Satoh T, Doi T, Ohtsu A, Tsuji A, Omuro Y, Mukaiyama A, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–49. https://doi.org/10.1200/JCO.2013.53.6136.

19.

Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, et al. Toward a treatment sequencing strategy: a systematic review of treatment regimens in advanced gastric cancer/gastroesophageal junction adenocarcinoma. Oncologist. 2021;26(10):e1704–29. https://doi.org/10.1002/onco.13907.CrossRefPubMedPubMedCentral

20.

Huang M, Li J, Yu X, Xu Q, Zhang X, Dai X, et al. Comparison of efficacy and safety of third-line treatments for advanced gastric cancer: a systematic review with Bayesian network meta-analysis. Front Oncol. 2021;11:734323. https://doi.org/10.3389/fonc.2021.734323.

21.

Zheng Y, Zhu XQ, Ren XG. Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(24):e6884. https://doi.org/10.1097/MD.0000000000006884.

22.

Zhu X, Ko YJ, Berry S, Shah K, Lee E, Chan K. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer. 2017;20(4):646–54. https://doi.org/10.1007/s10120-016-0656-7.CrossRefPubMed

23.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRef

24.

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. J Wiley & Sons, 2019.

25.

Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10. https://doi.org/10.1097/PRS.0b013e318219c171.CrossRefPubMedPubMedCentral

26.

Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950:607–11.

27.

Miller JJ. The inverse of the Freeman–Tukey double arcsine transformation. Am Stat. 1978;32(4):138.

28.

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.CrossRefPubMedPubMedCentral

29.

Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33(15):2521–37. https://doi.org/10.1002/sim.6111.CrossRefPubMed

30.

SAS Software version 9.4, Copyright © [2002–2012] SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. (2012). Accessed.

31.

R: A Language and Environment for Statistical Computing. https://www.R-project.org/(2020). Accessed.

32.

Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol. 2015;33(33):3858–65. https://doi.org/10.1200/JCO.2014.60.0320.CrossRefPubMed

33.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1637–51. https://doi.org/10.1016/S1470-2045%2817%2930682-4.CrossRefPubMed

34.

Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275.CrossRefPubMedPubMedCentral

35.

Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park Y, Koo DH, Lu JW, Xu J, Bhagia P, Kuang S, Shih CS, Qin S. Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1–positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial. J Clin Oncol. 2020;38:15_suppl, e16586-e16586

36.

Kang YK, Kang WK, Di Bartolomeo M, Chau I, Yoon HH, Cascinu S, Ryu MH, Kim JG, Lee KW, Oh SC, Takashima A. Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric cancer who failed≥ 2 prior chemotherapy regimens. Ann Oncol. 2019 Oct 1;30:v877-8.

37.

Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018;29(5):1220–6. https://doi.org/10.1093/annonc/mdy055.

38.

Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS, Yoon S, et al. Multi-center randomized phase ii study of weekly docetaxel Versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Res. 2015;35(6):3531–6.PubMed

39.

Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, et al. A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine. Cancer Res Treat. 2017;49(3):706–16. https://doi.org/10.4143/crt.2016.216.

40.

Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, et al. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist. 2019;24(1):18–24. https://doi.org/10.1634/theoncologist.2018-0142.CrossRefPubMed

41.

Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-Arm, phase II trial. J Clin Oncol. 2013;31(26):3219–25. https://doi.org/10.1200/JCO.2013.48.8585.CrossRefPubMed

42.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–54. https://doi.org/10.1200/JCO.2015.63.5995.CrossRefPubMed

43.

Lorenzen S, Knorrenschild JR, Pauligk C, Hegewisch‐Becker S, Seraphin J, Thuss‐Patience P, Kopp HG, Dechow T, Vogel A, Luley KB, Pink D. Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC). Int J Cancer. 2020a Nov 1;147(9):2493–502.

44.

Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/JCO.19.03077.CrossRefPubMed

45.

Maruta F, Ishizone S, Hiraguri M, Fujimori Y, Shimizu F, Kumeda S, et al. A clinical study of docetaxel with or without 5’DFUR as a second-line chemotherapy for advanced gastric cancer. Med Oncol. 2007;24(1):71–5. https://doi.org/10.1007/BF02685905.CrossRefPubMed

46.

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, et al. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer. 2016;16(1)(no pagination)(699). https://doi.org/10.1186/s12885-016-2736-9.

47.

Nakanishi K, Kobayashi D, Mochizuki Y, Ishigure K, Ito S, Kojima H, et al. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). Int J Clin Oncol. 2016;21(3):557–65. https://doi.org/10.1007/s10147-015-0919-z.CrossRefPubMed

48.

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery. ClinicalTrials.gov identifier: NCT00991952. https://ClinicalTrials.gov/show/NCT00991952

49.

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer. ClinicalTrials.gov identifier: NCT01579578. https://clinicaltrials.gov/show/NCT01579578

50.

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER). ClinicalTrials.gov identifier: NCT02178956. https://clinicaltrials.gov/ct2/show/NCT02178956

51.

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer. ClinicalTrials.gov Identifier: NCT02514551. https://ClinicalTrials.gov/show/NCT02514551

52.

Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, et al. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015;51(7):808–16. https://doi.org/10.1016/j.ejca.2015.02.009.CrossRefPubMed

53.

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013;24(6):1567–73. https://doi.org/10.1093/annonc/mdt002.CrossRefPubMed

54.

Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 2015;18(4):824–32. https://doi.org/10.1007/s10120-014-0420-9.CrossRefPubMed

55.

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–48. https://doi.org/10.1016/S1470-2045%2818%2930739-3.

56.

Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277–87. https://doi.org/10.1016/S2468-1253%2816%2930219-9.CrossRefPubMed

57.

Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, et al. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer. 2014;110(2):271–7. https://doi.org/10.1038/bjc.2013.726.CrossRefPubMed

58.

Su D. Clinical efficacy and safety of apatinib for treating stomach cancer and its effect on serum CA72-4, CEA and CA19-9. Acta Med Mediterr. 2020;36(3):1621–5.

59.

Sym SJ, Hong J, Park J, Cho EK, Lee JH, Park YH, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013;71(2):481–8. https://doi.org/10.1007/s00280-012-2027-3.CrossRefPubMed

60.

Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015;26(9):1916–22. https://doi.org/10.1093/annonc/mdv265.CrossRefPubMed

61.

Lorenzen S, Thuss-Patience PC, Pauligk C, Goekkurt E, Ettrich TJ, Lordick F, Stahl M, Reichardt P, Soekler M, Pink D, Probst S. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO. J Clin Oncol. 2020b May 20;38(15_suppl):4514–14. https://doi.org/10.1200/JCO.2020.38.15_suppl.4514.

62.

Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14. https://doi.org/10.1016/j.ejca.2011.06.002.CrossRefPubMed

63.

Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316–24. https://doi.org/10.1093/annonc/mdx107.CrossRefPubMed

64.

Wang F, Ren C, Xu J, Wang Z, He MM, Qiu M, Jin Y, Luo H, Wang F, Li Y, Tan Q. Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial. J Clin Oncol. 39, no. 15_suppl. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16022.

65.

Zhao X, Guo W, Chen Z, Zhang X, Zhu X, Zhang W, Yang L, Qiu L, Wang C, Huang M, Yu H, Li J, Zhang Z, Li W. Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: a randomized phase II trial. J Clin Oncol. 37, no. 15_suppl (May 20, 2019) 4054-4054. https://doi.org/10.1200/JCO.2019.37.15_suppl.4054.

66.

Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1015–24. https://doi.org/10.1016/S2468-1253(21)00313-7.CrossRefPubMed

67.

Yi JH, Lee J, Park SH, Park JO, Yim DS, Park YS, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer. 2012;106(9):1469–74. https://doi.org/10.1038/bjc.2012.100.CrossRefPubMedPubMedCentral

68.

Fushida S, Kinoshita J, Kaji M, Oyama K, Hirono Y, Tsukada T, et al. Paclitaxel plus valproic acid versus paclitaxel alone as second-or third-line therapy for advanced gastric cancer: a randomized phase II trial. Drug Des Dev Ther. 2016;10:2353–8. https://doi.org/10.2147/DDDT.S110425.CrossRef

69.

Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, et al. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer. 2016;19(3):902–10. https://doi.org/10.1007/s10120-015-0542-8.CrossRefPubMed

70.

Kahraman S, Yalcin S. Recent advances in systemic treatments for HER-2 positive advanced gastric cancer. Onco Targets Ther. 2021;14:4149–62. https://doi.org/10.2147/OTT.S315252.CrossRefPubMedPubMedCentral

71.

Zheng T, Jin J, Zhang Y, Zhou L. Efficacy and safety of paclitaxel with or without targeted therapy as second-line therapy in advanced gastric cancer: a meta-analysis. Medicine (Baltimore). 2020;99(25):e20734. https://doi.org/10.1097/md.0000000000020734.

72.

Smyth EC, Moehler M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol. 2019;11:1758835919867522. https://doi.org/10.1177/1758835919867522.CrossRefPubMedPubMedCentral

73.

Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188615. https://doi.org/10.1016/j.bbcan.2021.188615.

74.

Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.CrossRefPubMed

Title: Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
Authors: Lauren A. Abderhalden
Ping Wu
Mayur M. Amonkar
Brian M. Lang
Sukrut Shah
Fan Jin
Andrew M. Frederickson
Ali Mojebi
Publication date: 23-05-2023
Publisher: Springer US
Keywords: Gastric Cancer
Gastric Cancer
Targeted Therapy
Ramucirumab
Cytostatic Therapy
Published in: Journal of Gastrointestinal Cancer / Issue 4/2023
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-023-00932-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Attitudes of Gastroenterologists Regarding Delivery of Cancer Diagnoses: a Cross-Sectional Study

Diagnostic Utility of NLR, PLR and MLR in Early Diagnosis of Gastric Cancer: an Analytical Cross-Sectional Study

Tooth Loss as a Predictor of Postoperative Complications and Prognosis in Patients with Colorectal Cancer

Frontal Sinus Metastasis from Colonic Adenocarcinoma: a Case Report and Review of the Literature

Ileal Neuroendocrine Tumors Detected During Screening or Diagnostic Colonoscopy — Case Series and Comparison of Tumor Characteristics

Colorectal Lip Metastasis: A Rare Presentation of a Common Cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials